Drug Target Review

DECEMBER 13, 2023

Combinatorial analytics approaches identify combinations of features that together are associated with the disease phenotype in patient sub-groups, capturing the non-linear effects of interactions between multiple genes. The combinatorial approach is considerably more sensitive than GWAS and requires much smaller patient populations.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

The Pharma Data

JUNE 2, 2022

Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. pneumoniae invasive disease and pneumonia in adults 50 years and above.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. Autoimmune diseases affect more than 24 million people in the U.S.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

MAY 31, 2022

Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. pneumoniae invasive disease and pneumonia in adults 50 years and above. Pneumococcal disease.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Broad Institute

OCTOBER 11, 2023

He also read everything he could about her disease, including emerging evidence that suggested that the immune system could recognize and kill Merkel cell carcinoma. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

Creative Biolabs

JULY 12, 2020

They are currently working with Boehringer Ingelheim to further identify and develop these antibodies. They are expected to enter clinical development later this year. ” The researchers studied the SARS-CoV-2 antibody response of 12 people who recovered from COVID-19. .”

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

MAY 15, 2023

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. About XinThera XinThera is a private biotechnology company whose mission is to develop best-in-class small molecule drugs to treat cancer and immunologic diseases.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 12, 2021

Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

FEBRUARY 22, 2021

(Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly.

Clinical Development 40

Clinical Development Small Molecule Clinical Trials Immune Response 40

The Pharma Data

SEPTEMBER 29, 2020

from Australian investors to progress the INNA-051 clinical development programme. By boosting the natural immune response of the ferrets with our treatment, we’ve seen a rapid eradication of the virus,” said Christophe Demaison, managing director of Ena Respiratory. “If So far, Ena has raised AU$11.7m

Small Molecule 52

Small Molecule Immune Response Virus Treatment 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

NOVEMBER 10, 2020

P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Phase1b/2 clinical study to be conducted in the United States and several European countries. Billion by 2025. and Europe.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Interim analysis from Phase 1/2a First-in-Human trial supports further clinical development of investigational vaccine candidate JNJ-78436735 (also known as Ad26.COV2.S). Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 26, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. The first patient has been dosed in the EU. About FixVac.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

PerkinElmer

JANUARY 25, 2023

Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.

Science 52

Science Laboratories Immune Response Disease 52

Drug Target Review

JANUARY 15, 2024

As T cells develop, chromosomal DNA encoding the TCR of the CD8 T cells of each individual is rearranged and ‘educated’ to respond only to peptides presented in the context of a specific HLA Class I molecule present in that individual. Many potential candidate antigens are under consideration. Engineering soluble T-cell receptors for therapy.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Everything started in school with an experiment on isolating DNA from bananas.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

OCTOBER 25, 2020

We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co.,

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52

The Pharma Data

JANUARY 3, 2021

We are very honored to have someone of Dr. Zeldis’ caliber lead our scientific research and clinical development teams. It is my privilege to advise NexImmune as it seeks to develop novel treatments for melanoma and other cancers,” stated Dr. Weber. . GAITHERSBURG, Md., GAITHERSBURG, Md.,

Immune Response 40

Immune Response Clinical Trials Therapies Cell Biology 40

The Pharma Data

OCTOBER 27, 2020

The company’s lead program is aimed at Friedrich’s Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. AavantiBio has a unique opportunity to change the lives of those living with FA and other rare diseases,” Cumbo said. and China. said of B cells’ potential. “We

Small Molecule 52

Small Molecule Immune Response Therapies Clinical Development 52

The Pharma Data

JANUARY 21, 2021

Its core therapeutic areas are immuno-oncology, autoimmune disorders, and infectious diseases. RRP is a rare, difficult-to-treat and sometimes fatal disease of the upper and lower respiratory tracts. The National Institutes of Health (NIH) is planning on taking over manufacturing and clinical development.

Immune Response 52

Immune Response Laboratories Trials Therapies 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

OCTOBER 9, 2021

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About Ulcerative Colitis.

Disease 52

Disease Trials Science Immune Response 52

The Pharma Data

AUGUST 17, 2021

In the Opdivo plus Yervoy arm, patients received treatment with Opdivo 3 mg/kg every 2 weeks and Yervoy 1 mg/kg every 6 weeks up to 24 months or until disease progression or unacceptable toxicity. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

OCTOBER 21, 2020

Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. The active IND enables the Company to initiate the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients. MENLO PARK, Calif.

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

NOVEMBER 12, 2020

The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 The data will be presented in due course.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

JANUARY 17, 2021

LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies (MCTs) and targeted nanoparticle (TNP) therapeutics.

Therapies 40

Therapies Clinical Trials Disease Immune Response 40

The Pharma Data

MARCH 29, 2022

Spinner, MD, Consulting Physician Infectious Diseases and Pandemic Officer at the University Hospital Rechts der Isar and adjunct teaching professor at the Technical University of Munich, Munich, Germany, said: “Increasing COVID-19 cases, driven by the highly-transmissible BA.2 1-3 Evusheld was generally well-tolerated in the trial.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

APRIL 9, 2021

The results for these Opdivo -based combinations represent a significant advancement for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options,” said Ian M. development lead, gastrointestinal cancers, Bristol Myers Squibb. Waxman, M.D., About Opdivo.

Clinical Trials 52

Clinical Trials Trials Immune Response Treatment 52

The Pharma Data

MARCH 29, 2022

“Lung cancer is the leading cause of cancer deaths globally, and unfortunately cases caught in earlier stages continue to contribute to this statistic, with up to 55% of patients who undergo surgery ultimately relapsing and dying of their disease,” said Abderrahim Oukessou, M.D., About Opdivo.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

The Pharma Data

JANUARY 3, 2021

Preclinical data from our laboratory have shown that the nasal administration of anti-CD3 stimulates Tregs that can suppress inflammation and ameliorate inflammatory diseases. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. . NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

NOVEMBER 1, 2020

Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Clinical Data Expected by End of Year. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses shown to cause lung damage in COVID-19. NEW YORK and LONDON, Nov.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52